LeMaitre Vascular, Inc. (LMAT) To Go Ex-Dividend on May 21st

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced a quarterly dividend on Tuesday, April 28th. Shareholders of record on Thursday, May 21st will be given a dividend of 0.25 per share by the medical instruments supplier on Thursday, June 4th. This represents a c) annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Thursday, May 21st.

LeMaitre Vascular has raised its dividend payment by an average of 0.2%per year over the last three years and has raised its dividend every year for the last 14 years. LeMaitre Vascular has a dividend payout ratio of 42.0% meaning its dividend is sufficiently covered by earnings. Equities analysts expect LeMaitre Vascular to earn $3.27 per share next year, which means the company should continue to be able to cover its $1.00 annual dividend with an expected future payout ratio of 30.6%.

LeMaitre Vascular Stock Up 3.6%

LeMaitre Vascular stock opened at $100.83 on Tuesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of 37.21, a price-to-earnings-growth ratio of 2.70 and a beta of 0.60. LeMaitre Vascular has a fifty-two week low of $78.35 and a fifty-two week high of $118.01. The stock’s fifty day moving average is $109.23 and its two-hundred day moving average is $95.02.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.02. The company had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.LeMaitre Vascular’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Analysts predict that LeMaitre Vascular will post 3 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director David B. Roberts sold 8,464 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the sale, the director owned 17,979 shares of the company’s stock, valued at $1,920,157.20. This trade represents a 32.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO George W. Lemaitre sold 27,881 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the transaction, the chief executive officer owned 1,430,019 shares in the company, valued at $155,428,765.11. This trade represents a 1.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 269,891 shares of company stock worth $28,969,086 in the last ninety days. 7.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Large investors have recently added to or reduced their stakes in the business. Sound Income Strategies LLC lifted its position in LeMaitre Vascular by 425.6% during the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 183 shares during the period. Catalyst Capital Advisors LLC purchased a new position in LeMaitre Vascular during the first quarter worth about $32,000. Cornerstone Planning Group LLC lifted its position in LeMaitre Vascular by 534.0% during the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 283 shares during the period. MAI Capital Management purchased a new position in LeMaitre Vascular during the third quarter worth about $38,000. Finally, Geneos Wealth Management Inc. lifted its position in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.